Bellevue Group’s Biogen BIIB Stock Holding History

Bellevue Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-160	Closed	-$7K	–	210
2020 Q1	$7K	Hold	160	–	–	﹤0.01%	215
2019 Q4	$8K	Buy	+160	New	+$44.4K	﹤0.01%	216

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group's BIIB Position: Q2 2026 in Review

Bellevue Group reduced its Biogen (BIIB) stake by 91% in Q2 2026, selling an estimated $634K and leaving 338 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #136.

Bellevue Group first reported a position in BIIB in Q1 2016 and has held it in 41 quarters since. The position peaked at $183M in Q2 2021. 1,042 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Bellevue Group held 338 shares of Biogen worth $73K as of Q2 2026.
Bellevue Group sold 3,315 Biogen shares in Q2 2026, an estimated $634K.
Biogen made up ﹤0.01% of Bellevue Group's portfolio in Q2 2026, its #136 holding.
Bellevue Group first reported a position in Biogen in Q1 2016 and has held it in 41 quarters since.
Bellevue Group's Biogen position peaked at $183M in Q2 2021.
1,042 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.